Efficacy and safety of peptide receptor radionuclide therapy (PRRT) in patients with chronic kidney disease (CKD)

#3206

Introduction: The kidney is a dose-limiting organ in PRRT. Most clinical studies have focused on the safety of PRRT with normal or mildly impaired kidney function.

Aim(s): The aim of this study is to assess the efficacy and safety of 177-Lu DOTATATE in patients with NETs with eGFR between (30-60).

Materials and methods: A retrospective analysis of 55 patients with eGFR

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Alsadik S, Gnanasegaran G, Chen L, Toumpanakis C, Caplin M,

Keywords: neuroendocrine tumor, peptide receptor radionuclide therapy PRRT, 177lu-DOTATATE, chronic kidney disease,